- Home
- MGRC vs MIRM Comparison
MGRC vs MIRM Comparison
Compare MGRC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRC
- MIRM
- Stock Information
- Founded
- MGRC 1979
- MIRM 2018
- Country
- MGRC United States
- MIRM United States
- Employees
- MGRC N/A
- MIRM 349
- Industry
- MGRC Diversified Commercial Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- MGRC Consumer Discretionary
- MIRM Health Care
- Exchange
- MGRC Nasdaq
- MIRM Nasdaq
- Market Cap
- MGRC 2.8B
- MIRM 3.7B
- IPO Year
- MGRC N/A
- MIRM 2019
- Fundamental
- Price
- MGRC $115.92
- MIRM $72.85
- Analyst Decision
- MGRC Buy
- MIRM Strong Buy
- Analyst Count
- MGRC 2
- MIRM 11
- Target Price
- MGRC $147.50
- MIRM $76.09
- AVG Volume (30 Days)
- MGRC 131.2K
- MIRM 712.9K
- Earning Date
- MGRC 10-23-2025
- MIRM 11-11-2025
- Dividend Yield
- MGRC 1.68%
- MIRM N/A
- EPS Growth
- MGRC 117.49
- MIRM N/A
- EPS
- MGRC 10.26
- MIRM N/A
- Revenue
- MGRC $941,536,000.00
- MIRM $429,161,000.00
- Revenue This Year
- MGRC $6.28
- MIRM $53.14
- Revenue Next Year
- MGRC $5.25
- MIRM $19.83
- P/E Ratio
- MGRC $11.28
- MIRM N/A
- Revenue Growth
- MGRC 8.78
- MIRM 62.33
- 52 Week Low
- MGRC $97.81
- MIRM $36.88
- 52 Week High
- MGRC $129.93
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- MGRC 35.99
- MIRM 56.46
- Support Level
- MGRC $112.98
- MIRM $70.49
- Resistance Level
- MGRC $117.89
- MIRM $74.96
- Average True Range (ATR)
- MGRC 2.12
- MIRM 1.82
- MACD
- MGRC -0.69
- MIRM -0.72
- Stochastic Oscillator
- MGRC 11.24
- MIRM 51.03
About MGRC McGrath RentCorp
McGrath RentCorp is a rental company. It is comprised of four reportable business segments namely Modular building segment (Mobile Modular); Portable storage container segment (Portable Storage); Electronic test equipment segment (TRS-RenTelco); and its classroom manufacturing business selling modular buildings used as classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.